Seminars in hematology最新文献_第10页

Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana 非洲获得镰状细胞病基本治疗:来自加纳国家方案的经验。

IF 3.6 3区医学

Seminars in hematology Pub Date : 2023-09-01 DOI: 10.1053/j.seminhematol.2023.06.001

Christine Nyonator , Emefa Amoah , Etta Forson Addo , Maureen Mukanga , Augustine Kwabena Asubonteng , Kwaku Ohene-Frempong , Jonathan Michael Spector , Solomon Fiifi Ofori-Acquah

{"title":"Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana","authors":"Christine Nyonator , Emefa Amoah , Etta Forson Addo , Maureen Mukanga , Augustine Kwabena Asubonteng , Kwaku Ohene-Frempong , Jonathan Michael Spector , Solomon Fiifi Ofori-Acquah","doi":"10.1053/j.seminhematol.2023.06.001","DOIUrl":"10.1053/j.seminhematol.2023.06.001","url":null,"abstract":"<div><p>Novartis, a global medicines company, and the Sickle Cell Foundation of Ghana (SCFG), an advocacy organization, have endeavored to support the implementation of global best practices in the care of people living with sickle cell disease (SCD) in Africa, and to address unmet needs relating to this condition on the continent. Beginning in 2019, a multifaceted SCD program was implemented in Ghana through a public-private partnership involving the government of Ghana, the SCFG, Novartis, and other partners. A key component of the program involved expanding the reach of hydroxyurea (HU), the only approved disease-modifying generic treatment for SCD, in ways that would promote sustainable access. The program helped to raise the profile of SCD in Ghana and, in 2022, the government adopted HU into its National Health Insurance Scheme. Features of the effort in Ghana are now being expanded to other countries in Africa through cocreated programs with in-country partners. This article reviews the program's history, progress, challenges, and lessons learned.</p></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"60 4","pages":"Pages 226-232"},"PeriodicalIF":3.6,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0037196323000483/pdfft?md5=5b792d8fcf97d42a6ca5fea7e938097b&pid=1-s2.0-S0037196323000483-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9853742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Special edition of the Seminars in Hematology series on Global Hematology Care 全球血液病护理系列血液学研讨会特别版。

IF 3.6 3区医学

Seminars in hematology Pub Date : 2023-09-01 DOI: 10.1053/j.seminhematol.2023.09.003

Anna Schuh

引用次数: 0

Circulating tumor DNA in NK/T and peripheral T cell lymphoma NK/T和外周T细胞淋巴瘤的循环肿瘤DNA。

IF 3.6 3区医学

Seminars in hematology Pub Date : 2023-07-01 DOI: 10.1053/j.seminhematol.2023.07.003

Yu-Jia Huo , Wei-Li Zhao

引用次数: 0

Cell-free DNA in large B-cell lymphoma: MRD and beyond 大B细胞淋巴瘤的无细胞DNA：MRD及以后的研究。

IF 3.6 3区医学

Seminars in hematology Pub Date : 2023-07-01 DOI: 10.1053/j.seminhematol.2023.06.004

Brian J. Sworder , David M. Kurtz

引用次数: 0

outside front cover, PMS 8883 metallic AND 4/C 外前盖，PMS 8883金属AND 4/C

IF 3.6 3区医学

Seminars in hematology Pub Date : 2023-07-01 DOI: 10.1053/S0037-1963(23)00060-4

引用次数: 0

Special issue on circulating tumor DNA: Introductory editorial 循环肿瘤DNA特刊：引言。

IF 3.6 3区医学

Seminars in hematology Pub Date : 2023-07-01 DOI: 10.1053/j.seminhematol.2023.08.001

Adalgisa Condoluci , Davide Rossi

引用次数: 0

Clinical applications of circulating tumor DNA in indolent B-cell lymphomas 循环肿瘤DNA在惰性B细胞淋巴瘤中的临床应用。

IF 3.6 3区医学

Seminars in hematology Pub Date : 2023-07-01 DOI: 10.1053/j.seminhematol.2023.06.003

Rahul Lakhotia, Mark Roschewski

{"title":"Clinical applications of circulating tumor DNA in indolent B-cell lymphomas","authors":"Rahul Lakhotia, Mark Roschewski","doi":"10.1053/j.seminhematol.2023.06.003","DOIUrl":"10.1053/j.seminhematol.2023.06.003","url":null,"abstract":"<div><p><span><span><span>Indolent B-cell lymphomas are generally incurable with standard therapy and most patients have a prolonged disease course that includes multiple treatments and periods of time in which they do not require therapy. Currently available tools to monitor </span>disease burden and define response to treatment rely heavily on imaging scans that lack tumor specificity are unable to detect disease at the molecular level. </span>Circulating tumor DNA (ctDNA) is a versatile and promising biomarker being developed across multiple lymphoma subtypes. Advantages of ctDNA include high tumor specificity and limits of detection that are significantly lower than imaging scans. Potential clinical applications of ctDNA in indolent B-cell lymphomas include baseline prognostication, early signs of treatment resistance, measurements of minimal residual disease, and a noninvasive method to directly monitor disease burden and clonal evolution after therapy. Clinical applications of ctDNA have not yet proven clinical utility but are increasingly used as translational endpoints in </span>clinical trials testing novel approaches and the analytic techniques used for ctDNA continue to evolve. Advances in therapy for indolent B-cell lymphomas include novel targeted agents and combinations that achieve very high rates complete response which amplifies the need to improve our current methods to monitor disease.</p></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"60 3","pages":"Pages 164-172"},"PeriodicalIF":3.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10332704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas 血液从未如此粘稠：B细胞淋巴瘤液体活检工具箱中的无细胞DNA碎片学。

IF 3.6 3区医学

Seminars in hematology Pub Date : 2023-07-01 DOI: 10.1053/j.seminhematol.2023.06.006

Leo Meriranta , Esa Pitkänen , Sirpa Leppä

{"title":"Blood has never been thicker: Cell-free DNA fragmentomics in the liquid biopsy toolbox of B-cell lymphomas","authors":"Leo Meriranta , Esa Pitkänen , Sirpa Leppä","doi":"10.1053/j.seminhematol.2023.06.006","DOIUrl":"10.1053/j.seminhematol.2023.06.006","url":null,"abstract":"<div><p><span><span>Liquid biopsies utilizing plasma </span>circulating tumor DNA<span> (ctDNA) are anticipated to revolutionize decision-making in cancer care. In the field of lymphomas, ctDNA-based blood tests represent the forefront of clinically applicable tools to harness decades of genomic research for disease profiling, quantification, and detection. More recently, the discovery of nonrandom fragmentation patterns in cell-free DNA (cfDNA) has opened another avenue of liquid biopsy research beyond mutational interrogation of ctDNA. Through examination of structural features, nucleotide content, and genomic distribution of massive numbers of plasma cfDNA molecules, the study of fragmentomics aims at identifying new tools that augment existing ctDNA-based analyses and discover new ways to profile cancer from blood tests. Indeed, the characterization of aberrant lymphoma ctDNA fragment patterns and harnessing them with powerful machine-learning techniques are expected to unleash the potential of nonmutant molecules for liquid biopsy purposes. In this article, we review cfDNA fragmentomics as an emerging approach in the ctDNA research of B-cell lymphomas. We summarize the biology behind the formation of cfDNA fragment patterns and discuss the preanalytical and technical limitations faced with current methodologies. Then we go through the advances in the field of lymphomas and envision what other noninvasive tools based on fragment characteristics could be explored. Last, we place fragmentomics as one of the facets of ctDNA analyses in emerging multiview and multiomics liquid biopsies. We pay attention to the unknowns in the field of </span></span>cfDNA fragmentation<span> biology that warrant further mechanistic investigation to provide rational background for the development of these precision oncology tools and understanding of their limitations.</span></p></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"60 3","pages":"Pages 132-141"},"PeriodicalIF":3.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10628491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical applications of circulating tumor DNA in Hodgkin lymphoma 循环肿瘤DNA在霍奇金淋巴瘤中的临床应用。

IF 3.6 3区医学

Seminars in hematology Pub Date : 2023-07-01 DOI: 10.1053/j.seminhematol.2023.06.005

Jan-Michel Heger , Justin Ferdinandus , Julia Mattlener , Sven Borchmann

引用次数: 0

Clinical applications of circulating tumor DNA in central nervous system lymphoma 循环肿瘤DNA在中枢神经系统淋巴瘤中的临床应用。

IF 3.6 3区医学

Seminars in hematology Pub Date : 2023-07-01 DOI: 10.1053/j.seminhematol.2023.06.007

Anna Katharina Foerster , Eliza M. Lauer , Florian Scherer

{"title":"Clinical applications of circulating tumor DNA in central nervous system lymphoma","authors":"Anna Katharina Foerster , Eliza M. Lauer , Florian Scherer","doi":"10.1053/j.seminhematol.2023.06.007","DOIUrl":"10.1053/j.seminhematol.2023.06.007","url":null,"abstract":"<div><p><span>Detection and characterization of circulating tumor DNA<span><span> (ctDNA) in body fluids have the potential to revolutionize management of patients with lymphoma. Minimal access to malignant DNA through a simple blood draw or lumbar puncture is particularly appealing for CNS lymphomas (CNSL), which cannot be easily or repeatedly sampled without invasive surgeries. Profiling of ctDNA provides a real-time snapshot of the genetic composition </span>in patients<span> with CNSL and enables ultrasensitive quantification of lymphoma burden at any given time point during the course of the disease. Here, we broadly review technical challenges of ctDNA identification in CNSL, recent advances of innovative liquid biopsy technologies, potential clinical applications of ctDNA and how it may improve CNSL </span></span></span>risk stratification<span><span>, outcome prediction, and monitoring of measurable residual disease. Finally, we discuss </span>clinical trials<span> and scenarios in which ctDNA could be implemented to guide risk-adapted and personalized treatment decisions.</span></span></p></div>","PeriodicalId":21684,"journal":{"name":"Seminars in hematology","volume":"60 3","pages":"Pages 150-156"},"PeriodicalIF":3.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10645954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0